Nursing Considerations in the Neoadjuvant Treatment of HER2+ Breast Cancer

PROGRAM OVERVIEW: This program will discuss the use of PERJETA® (pertuzumab) for the neoadjuvant treatment of HER2+ early breast cancer, focusing on clinical trial data, eligibility, and safety.

Presented By
Tatiana Saverino, NP
University of Pennsylvania Health System
Berwyn, PA

Genentech Hosts
Susan Martin
(516)263-2090
susanmar@gene.com

Edith Fusco
(973)868-6011
fusco.edith@gene.com

Michelle Pierce
(732)859-1493
piercem3@gene.com

Program Date and Location
Tuesday, June 6, 2017
Steakhouse 85
85 Church Street, New Brunswick, NJ 08901

Schedule of Events
Registration: 6:00PM
Program: 6:30PM

Event Code
PRF75590
Please RSVP and provide your name, credentials, and institutional affiliation by
Friday, June 2, 2017 by 6:00PM
by emailing the event host.

Indication
PERJETA® (pertuzumab) is a HER2/neu receptor antagonist indicated for:
- Treatment of metastatic breast cancer in combination with Herceptin® (trastuzumab) and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease
- Use in combination with trastuzumab and docetaxel as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on demonstration of an improvement in pathological complete response rate. No data are available demonstrating improvement in event-free survival or overall survival

Limitations of Use:
- The safety of PERJETA as part of a doxorubicin-containing regimen has not been established
- The safety of PERJETA administered for greater than 6 cycles for early breast cancer has not been established

Boxed WARNINGS: Left Ventricular Dysfunction and Embryo-Fetal Toxicity
- PERJETA administration can result in subclinical and clinical cardiac failure manifesting as decreased LVEF and CHF. Evaluate cardiac function prior to and during treatment. Discontinue PERJETA treatment for a confirmed clinically significant decrease in left ventricular function
- Exposure to PERJETA can result in embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception

Please see additional select Important Safety Information throughout, and the accompanying full Prescribing Information, including Boxed WARNINGS.
Important Safety Information

Boxed WARNINGS: Left Ventricular Dysfunction and Embryo-Fetal Toxicity

• PERJETA administration can result in subclinical and clinical cardiac failure manifesting as decreased LVEF and CHF. Evaluate cardiac function prior to and during treatment. Discontinue PERJETA treatment for a confirmed clinically significant decrease in left ventricular function.

• Exposure to PERJETA can result in embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception.

Additional Important Safety Information

• PERJETA is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients.

• PERJETA has been associated with infusion and hypersensitivity reactions/anaphylaxis.

• Detection of HER2 protein overexpression is necessary for selection of patients appropriate for PERJETA therapy.

• In the treatment of MBC, the most common adverse reactions (> 30%) seen with PERJETA in combination with Herceptin and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy.

Most Common Adverse Reactions in Neoadjuvant Treatment of Breast Cancer:

• The most common adverse reactions (> 30%) with PERJETA in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia.

• The most common adverse reactions (> 30%) with PERJETA in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of FEC were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia.

• The most common adverse reactions (> 30%) with PERJETA in combination with docetaxel, carboplatin, and trastuzumab (TCH) were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see additional select Important Safety Information throughout, and the accompanying full Prescribing Information, including Boxed WARNINGS.